Fixed versus titrated interferon-α(2B) in chronic hepatitis C. A randomized controlled multicenter trial

Journal of Hepatology

Volumn 25, Issue 3, 1996, Pages 275-282

  Reichen, Jurg ^a   Bianchi, Leonardo ^a   Bühler, Hugo ^a   Dolivo, Nicolas ^a   Gonvers, Jean Jacques ^a   Lavanchy, Daniel ^a   Malé, Pierre Jean ^a   Renner, Eberhard L ^a   Solioz, Marc ^a   Schmid, Martin ^a   Zimmermann, Arthur ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Galactose elimination disparity; Liver biopsy; Surrogate markers; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; GALACTOSE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CANDIDIASIS; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DERMATITIS; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; HYPOTHYROIDISM; INFLUENZA; LIVER BIOPSY; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TITRIMETRY;

EID: 10144241691     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(96)80112-7     Document Type: Article

References (38)

1. Tine F, Magrin S., Craxi A., Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J Hepatol. 13:1991;192-199.
2. Davis GL., Balart L.A., Schiff E.R., Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, van Thiel DH, Tamburro C, Lefkowitch JH, Albrecht J, Meschievitz C, Ortego TJ, Gibas A. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized-controlled trial. N Engl J Med. 321:1989;1501-1505.
3. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou J.P. Recombinant human alpha-interferon in patients with chronic nonA-nonB hepatitis: a multicenter randomized controlled trial from France. Hepatology. 13:1991;393-397.
4. Reichen J, Solioz M, Buhler H, Gonvers JJ, Knoblauch M, Lavanchy D, Male PJ, Meyer PJ, Meyer B, Schmid M, Bianchi L. Low-dose interferon in chronic hepatitis non-A non-B: effects on quantitative liver function and structure in a randomized, controlled multicenter trial. Clin Invest. 71:1993;888-893.
5. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med. 332:1995;1457-1462.
6. Aebli N, Reichen J. Prognostische Wertigkeit der seriellen Bestimmung der Galaktoseeliminationskapazitaet bei der chronischen Hepatitis. Schweiz Med Wochenschr. 121:1991;970-976.
7. Tygstrup N. Determination of the hepatic galactose elimination capacity after a single intravenous injection in man. Acta Physiol Scand. 58:1963;162-172.
8. Schmid M, FLury R, Buhler H, Havelka J, Grob PJ, Heitz PU. Chronic viral hepatitis B and C: an argument against the conventional classification of chronic hepatitis. Virchows Arch. 425:1994;221-228.
9. Hollander M, Wolfe D.A. Nonparametric Statistical Methods. 1973;Wiley, New York.
10. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, Trepo C. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A- non-B hepatitis. Gastroenterology. 101:1991;497-502.
11. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon a-2b. A multicenter study. Dig Dis Sci. 38:1993;612-618.
12. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal SR, Yun ZB, Weiland O. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha(2B) for 60 weeks. Hepatology. 19:1994;280-285.
13. Kleter GEM, Brouwer JT, Heijtink RA, Schalm SW, Quint WGV. Detection of hepatitis C virus RNA in patients with chronic hepatitis C virus infections during and after therapy with alpha interferon. Antimicrobial Agents Chemother. 37:1993;595-597.
14. Bosch O, Tapia L, Quiroga JA, Carreño V. An escalating dose regime of recombinant interferon-alpha 2A in the treatment of chronic hepatitis. J Hepatol. 17:1993;146-149.
15. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology. 15:1992;1013-1016.
16. Lau JYN, Mizokami M, Ohno T, Diamond D.A., Kniffen J, Davis Gl. Discrepancy between biochemical and virological responses to interferon alpha in chronic hepatitis C. Lancet. 342:1993;1208-1209.
17. Liang T, Rustgi V, Galun E, Blum H. HCV RNA in patients with chronic hepatitis C treated with interferon-α J Med Virol. 40:1993;69-75.
18. Pagliaro L, Craxi A, Camma C, Tine F, Di Marco V, Lo Iacono O, Almasio P. Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology. 19:1994;820-828.
19. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol. 20:1994;410-415.
20. Camps J, Garciagranero M, Riezuboj JI, Larrea E, DeAlava E, Civeira MP, Castilla A, Prieto J. Prediction of sustained remission of chronic hepatitis C after a 12-month course of alfa interferon. J Hepatol. 21:1994;4-11.
21. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, Kamada T. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology. 104:1993;877-883.
22. Magrin S, Craxi A, Fabiano C, Simonetti RG, Fiorentino G, Marino L, Diquattro O, DiMarco V, Loiacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchezpescador R, Detmer J, Wilber JC, Pagliaro L. Hepatitis C viremia in chronic liver disease - relationship to interferon-alpha or corticosteroid treatment. Hepatology. 19:1994;273-279.
23. Kanazawa Y, Hayashi N, Mita E, Li TC, Hagiwara H, Kasahara A, Fusamoto H, Kamada T. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology. 20:1994;1121-1130.
24. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, Hashimoto M, Iwasaki S, Kobeyashi M, Hiromitsu K. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology. 19:1994;1088-1094.
25. Hino K, Sainokami S, Shimoda K, Iino S, Wang Y, Okamoto H, Miyakawa Y, Mayumi M. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C. J Med Virol. 42:1994;299-305.
26. Diodati G, Bonetti P, Tagger A, Casarin C, Noventa F, Ribero M, Fasola M, Ruol A, Realdi G. Relationship between serum HCV markers and response to interferon therapy in chronic hepatitis C. Evaluation of HCV genotypes during and after long-term follow-up. Dig Dis Sci. 39:1994;2497-2502.
27. Booth JCL, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, Thomas HC. Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon α Gut. 36:1995;427-432.
28. David E, Pucci A, Palladin D, et al. Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A, non-B viral hepatitis. A randomized controlled trial. Am J Clin Pathol. 98:1992;397-401.
29. Reichard O, Glaumann H, Norkrans G, Wejstal R, Fryden A, Schvarcz R, Weiland O. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course. Liver. 14:1994;169-174.
30. De Alava E, Camps J, Pardo-Mindan J, Garcia-Granero M, Muñoz M, Sola J, Civeira MP, Contreras F, Vazquez JJ, Castilla A, Prieto J. Histological outcome of chronic hepatitis C treated with a 12-month course of lymphoblastoid alfa-interferon. Liver. 13:1993;73-79.
31. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C, Grimaud JA. Interferon-alpha(2b) therapy reduces liver fibrosis in chronic non-A non-B hepatitis: a quantitative histological evaluation. Hepatology. 18:1993;1344-1349.
32. Seeff LB, Buskell Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med. 327:1992;1906-1911.
33. Koretz R, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis Looking back in the second decade. Ann Intern Med. 119:1993;110-115.
34. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 332:1995;1463-1466.
35. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, Garcia N, Civeira MP. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J Interferon Res. 13:1993;279-282.
36. Martin J, Bosch O, Moraleda G, Bartolome J, Quiroga JA, Carreño V. Pilot study of recombinant human granulocytemacrophage colony-stimulating factor in the treatment of chronic hepatitis B. Hepatology. 18:1993;775-780.
37. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 337:1991;1058-1061.
38. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH. A pilot study of Ribavirin therapy for chronic hepatitis C. Hepatology. 16:1992;649-654.